We compared the effects of intraosseous BMT with those of standard i.v. BMT on the efficacy on donor-cell engraftment into the BM and lymphoid organs across an MHC barrier in rats. Twenty-four intraosseous and 24 i.v. BMTs were performed from 48 ACI (RT1 a ) donors to 48 Lewis (RT1 l ) recipients. Each transplant group received either intraosseous or i.v. BMT. Groups I and II served as controls without immunosuppression (n ¼ 16); groups III and IV received cyclosporine monotherapy (n ¼ 16); and V and VI received ab-TCR monoclonal antibody and cyclosporine A (ab-TCR/CsA) for 7 days (n ¼ 16). In each group, four rats received 35 Â 10 6 transplanted bone marrow cells (BMCs) and four received 70 Â 10 6 cells. All animals survived without GVHD. Mean (7s.d.) donorcell engraftment into BM of recipients after intraosseous BMT was 7.9% (71.3%) in recipients receiving ab-TCR-CsA and 70 Â 10 6 BMCs, and 4.2% (71.4%) in recipients after i.v. transplantation. The seeding efficacy of donor cells into lymphoid tissue was greater after intraosseous BMT and ab-TCR-CsA than after standard i.v. transplantation. In our model, intraosseous BMT facilitated donor-cell engraftment under short-term immunodepletive ab-TCR/CsA protocol, which resulted in a temporary state of immune unresponsiveness.
Introduction
Donor-specific unresponsiveness to a transplanted organ is one of the most challenging problems in solid organ and composite tissue allograft transplants. BMT in the absence of formal ablation of the recipient's hematopoietic system may ultimately induce in the recipient a specific unresponsiveness or hyporesponsiveness to any tissue or composite tissue allograft transplanted from the same BM donor. BMT induces chimerism that may persist after immunosuppressive therapy is discontinued, and as a consequence, may induce tolerance. Several groups have reported that immunosuppressive protocols augmented with donor BMT in solid organ transplant recipients induced chimerism and thus improved long-term allograft survival. [1] [2] [3] Only 10À20% of hematopoietic stem cells transplanted intravenously graft to the BM; this represents a low seeding efficiency. 4, 5 In contrast, intra-bone BMT reveals a 15-fold greater potential for hematopoietic stem cell engraftment. 6 Because the ability of donor stem cells to enter the BM is not as effective after i.v. administration, we also explored the effects of route and dosage of bone marrow cell (BMC) administration on donor-cell engraftment.
GVHD did not develop after intra-bone allogeneic BMT, even when whole BM was injected (including small populations of T cells). 7 Grafts also did not fail after intra-bone BMT under conditioning regimens (radiation). Hematopoietic recovery was rapid and T-cell function was restored. [4] [5] [6] [7] [8] [9] [10] [11] [12] Recently this promising new strategy of intraosseous stem cell engraftment was applied in nonhuman primates under conditioning with radiation. 13 We previously reported the effect of different routes and dosages of BMC transplantation on chimerism induction in the peripheral blood.
14 Intraosseous transplantation of BMC under an ab-TCR and cyclosporine A (ab-TCR/CsA) protocol proved to be 75% more efficient in inducing donor-specific chimerism than under i.v. transplantation. 14 The goal of this study was to further explore the effect of intraosseous BMT on hematopoietic recovery. We compared the effects of intraosseous BMT with those of standard i.v. BMT on the efficacy of donor-cell engraftment into the lymphoid organs and BM compartment of recipients as well as chimerism induction across an MHC barrier under our established 7-day protocol of ab-TCR/ CsA therapy in a fully MHC-mismatched rat model.
Materials and methods

Animals and experimental groups
'Guide for the Care and Use of Laboratory Animals' published by the National Institutes of Health. The animals were caged individually with the 12-h light-dark cycle, and standard laboratory food and water were available ad libitum.
We transplanted BMC from 48 August Copenhagen Irish (ACI, RT1 a ) rats to 48 Lewis (LEW, RT1 1 ) rats (Harlan Sprague-Dawley, Indianapolis, IN, USA) weighing 200 g. Rats were anesthetized with an i.p. injection of sodium pentobarbital (50 mg/kg). The effects of BMC engraftment after either intraosseous or i.v. BMT were studied in six groups of eight animals each (Table 1) . Each group was further divided into two subgroups that received either 35 Â 10 6 (n ¼ 4) or 70 Â 10 6 (n ¼ 4) of transplanted BMC. Groups I and II served as controls, receiving either intraosseous or i.v. BMT but not immunosuppression. Groups III and IV received either intraosseous or i.v. BMT and CsA monotherapy, whereas groups V and VI received either intraosseous or i.v. BMT and ab-TCR/CsA therapy.
Immunosuppressive protocols
Groups III and IV received CsA monotherapy (16 mg/kg/d; Bedford Laboratories, Bedford, OH, USA) beginning on the day of BMT and continuing for 7 days post transplant. In groups V and VI, CsA (16 mg/kg/d) was administered subcutaneously, and 250-mg/d ab-TCR monoclonal antibody (mAb) (clone: R73; BD Bioscience Pharmingen Inc., San Diego, CA, USA) was given intraperitoneally. This combined immunosuppressive therapy was administered for only 7 days post transplant.
Clinical evaluation
All animals were evaluated clinically for signs of GVHD such as diffuse erythema (particularly of the ear), hyperkeratosis of the foot pads, dermatitis, weight loss, alopecia, dyspnea and diarrhea. 15 Animals were considered to exhibit GVHD if at least four of the above signs were observed.
Donor BM isolation and transplantation procedure Femoral and tibial bones were harvested from the donor rats and flushed into Medium 199 containing gentamicin 2 mg/ml. /kg) cells was performed via the femoral vein. Intraosseous BMT was performed through a lateral femoral incision. A burr hole was created in the bone with a 27-gauge needle. Before BM infusion, the same volume of recipients' BM (50 ml) was withdrawn from the femur. After the cells were injected into the femur, the hole was sealed with bone wax (Bone Wax, Ethicon, Johnson and Johnson, Somerville, NJ, USA) to prevent leaking. The incision was then closed in a two-layer fashion, including muscle and skin closure.
Detecting donor-specific chimerism in peripheral blood Two-color flow cytometry was used to evaluate the immunodepletion of T lymphocytes and the presence of donor-specific chimerism for MHC class I (RT1 a ) antigen in the peripheral blood. Donor-specific chimerism was assessed in the peripheral blood of recipient rats between 7 and 100 days post transplant and at the time of euthanasia, 250 days after BMT. Donor chimerism was assessed with combinations of conjugated mouse anti-rat RT1A 
Histopathologic assessment
To ascertain whether there were any architectural changes characteristic of GVHD in the spleen of BMC recipients at the time of euthanasia at 250 days after BMT, frozen sections of spleen were stained with hematoxylin and eosin and evaluated using the system described by Beschorner et al.
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Immunohistochemical analysis
The migratory potential of donor-origin cells into lymphoid tissues was evaluated in each of the recipients. Lymph nodes, thymus and spleen were harvested when the rats were euthanized, 250 days after BMT. Samples were immediately snap-frozen in liquid nitrogen and kept at À701C until used. Frozen sections (4 mm) of lymph node, spleen and thymus were fixed for 10 min in acetone, air-dried and blocked for endogenous peroxidase before incubation with mouse anti-rat RT1 a (for MHC class I) mAb for 30 min at room temperature. The binding of primary antibodies was detected using a Dako EnVision þ System, peroxidase (aminoethylcarbazole) (Dako, Carpinteria, CA, USA) in accordance with the manufacturer's instructions. Slides were counterstained in hematoxylin and mounted in Faramount. Semi-quantitative analysis was performed through assessing the number of donor-origin cells in five high-power fields (HPF) at Â 400 and was calculated as a mean value7s.d.
Statistical analysis
Results were reported as a mean value7s.d. Significance of differences between means was calculated using the Mann-Whitney U-test and Statistica StatSoft (Version 6.1). Differences among groups were considered significant at Po0.05.
Results
Assessment of GVHD
Clinical evaluation. BMC recipients were daily weighted for the first month and weekly thereafter, and monitored for clinical manifestations of GVHD. All animals maintained pre-transplanted weight during the follow-up period and were in good condition, without ear redness, hair loss, myoatrophy, diarrhea or dyspnea. Since all animals survived without clinical signs of GVHD, tissue samples were not harvested for ascertainment of the disease.
Donor-specific chimerism in peripheral blood. Chimerism after BMT was expressed as the presence of donor-origin cells specific for T-lymphocyte subpopulations (CD4/RT1 a and CD8/RT1 a ) and B-lymphocytes CD45RA/RT1 a . Total chimerism was calculated as a sum of T-and Blymphocytes CD4/RT1 a CD8/RT1 a and CD45RA/RT1 a , respectively, and is presented as a mean value (7s.d.) in Figure 1 . At day 7 after BMT, all transplanted groups exhibited a level of chimerism, which was higher after i.v. BMT than after intraosseous BMT (Figure 1 ). However, during the follow-up period, up to 100 days post transplant, the level of donor-origin cells was higher in groups that received BMC directly into the bone.
In control groups I and II (without treatment) and in groups III and IV, which received CsA monotherapy, the level of chimerism declined during the follow-up period in all groups, irrespective of the dose of transplanted BMC (Figure 1) .
ab-TCR/CsA protocol resulted in improved engraftment of donor cells compared with the groups that received no treatment and with those that received CsA monotherapy. In the ab-TCR/CsA (35 Â 10 6 cells) group, at day 100 post transplant, total chimerism was greater after intraosseous BMT compared with i.v. BM cell delivery (4.57 vs 2.80%; P ¼ 0.03) (Figure 1d ). Moreover, in the ab-TCR/CsAtreated group receiving 70 Â 10 6 BMC, total chimerism was significantly higher in animals which received BMC directly into the bone compared with standard i.v. BMT (8.51 vs 5.33%; P ¼ 0.01) (Figure 1d ).
The level of chimerism in the peripheral blood was also dose-dependent. Beginning from day 7 post transplant, when chimerism predominated in intravenously infused groups, delivery of 70 Â 10 6 BMC in ab-TCR/CsA-treated groups resulted in 10.7% of chimerism compared with 6.34% in groups which received 35 Â 10 6 BMC (P ¼ 0.02) (Figure 1a ). In the ab-TCR/CsA-treated group, intraosseous delivery of 70 Â 10 6 BMC resulted in total chimerism of 9.08% compared with 5.28% in groups which received 35 Â 10 6 BMC (P ¼ 0.03) (Figure 1a ). During the follow-up period, beginning with day 21 post transplant, the group that received intrabone transplant displayed higher chimerism, which was dose-dependent (Figure 1b-d) . When chimerism was established, at day 100 post transplant, animals which received 70 Â 10 6 BMC exhibited 8.51% total chimerism compared with 4.57% in groups infused with 35 Â 10 6 BMC (P ¼ 0.01) (Figure 1d ). Intravenous infusion of 70 Â 10 6 BMC resulted in 5.33% chimerism, whereas 35 Â 10 6 BMC delivery maintained chimerism at a level of 2.80% (P ¼ 0.02) (Figure 1d ).
When the animals were euthanatized at day 250 post transplant, chimerism levels were nearly equal after i.v. and intraosseous BMT in the control groups (Figure 2a) . In animals receiving CsA monotherapy and intraosseous 70 Â 10 6 BMC, chimerism was ascertained as 3.25 vs 2.06% (NS) after i.v. BMC transplantation. In recipients receiving ab-TCR/CsA protocol, chimerism was also higher after intraosseous transplantation of 70 Â 10 6 cells compared with i.v. BMC delivery and was ascertained as 4.45 vs 2.76%, respectively (P ¼ 0.020) (Figure 2a) . With regard to long-term survival, in animals that received ab-TCR/CsA therapy, the level of chimerism also depended on dose and route delivery: it exhibited 4.45% after intraosseous delivery of 70 Â 10 6 BMC compared with 2.77% following intraosseous delivery of 35 Â 10 6 BMC (P ¼ 0.02) (Figure 2a) . Donor-specific chimerism in BM. We confirmed the presence of donor-specific RT1 a positive cells in the BM of recipients on day 250 post transplant, the time of euthanasia. To examine the engraftment of donor cells, we stained BMCs from the recipients' contralateral femurs with donor-specific RT1 a mAb. At day 250 in the control groups, the mean proportion of donor-derived cells was 1.4% in the i.v. BMT group and 2.4% in the intraosseous BMT group (70 Â 10 6 cells). In the CsA-treated groups, donor chimerism was also higher in the intraosseous group than in the i.v. group that received 70 Â 10 6 BMC (Figure 2b ). The 7-day protocol of ab-TCR/CsA combined with transplantation of 70 Â 10 6 BMC resulted in a mean engraftment of 7.9% of donor cells after intraosseous BMT and in 4.2% engraftment after i.v. BMT ( Figure 2b ) (P ¼ 0.028).
The dosage of transplanted BMC was also reflected in the level of chimerism in the BM compartment of recipients. BMC engraftment into the recipient's BM under ab-TCR/CsA protocol revealed 40% greater efficiency after intraosseous BMT (70 Â 10 6 cells) compared with transplantation of 35 Â 10 6 BMC (7.9 vs 4.8%, respectively; P ¼ 0.02) (Figure 2b ). In addition, 7-day CsA monotherapy improved the engraftment of donor cells after a higher dose of intraosseous BMT (70 Â 10 6 cells) compared with BMC delivery (35 Â 10 6 ), 3.8 vs 2.2%, respectively (P ¼ 0.02).
Comparison of donor-cell engraftment into the BM compartment of recipients after different routes and dosages of BM delivery, and under different treatment protocols, is illustrated in Figure 2b .
Donor-derived cells in the lymphoid organs. Donor-derived cells were identified in the recipients' lymph nodes, spleen and thymus by staining with RT1 a mAb of donor MHC class I. The number of RT1 a donor cells was higher in the group receiving BMT under the ab-TCR/CsA protocol compared with other groups (Table 2) . RT1 a donor cells were localized in the spleen, in the white pulp, mainly at the junction of the B-and T-cell areas. The number of donorderived cells in the spleen was greater after intraosseous compared with i.v. BM delivery; specifically, 34.471.8 vs 28.074.4 (P ¼ 0.031), per HPF. Moreover, in the thymus, the number of donor-origin RT1 a cells was greater in those animals that received intraosseous BMT compared with those that received i.v. infusion; specifically, 6.671.3 vs 1.470.9 (P ¼ 0.007) per HPF ( Table 2) . Donor-derived cells in the thymus were present in the cortical zone ( Figure 3 ). Day 100 after BMT a positive cells in the peripheral blood of recipients between day 7 and day 100 after i.v. and intraosseous BMT. Significances of differences between means were calculated using the Mann-Whitney U-test. Differences among groups were considered significant at Po0.05.
Histologic evaluation
During euthanasia (on day 250 post transplant), spleens of BMC recipients were assessed for architectural changes as well as any sign of GVHD. The white pulp of the spleen in all groups exhibited normal cellularity with small lymphocytes in the follicles and periarteriolar regions. Active germinal centers of the follicles were surrounded by medium-sized lymphocytes in the mantle zone around the follicles. No signs of GVHD were evident in any of the study groups.
Discussion
Chimerism after allogeneic BMT offers an ideal platform for adoptive immunotherapy for hematologic disorders and solid organ transplantation, as well as composite tissue allograft transplants. The optimal immunosuppression strategy may consist of a nontoxic, non-myeloablative regimen that allows mixed hematopoietic chimerism to be established, with mutual donor-host tolerance and without the need for long-term immunosuppressive therapy. Such a strategy holds promise for clinical applications in the treatment of several disorders, including genetic diseases, immunodeficiency syndromes, inborn errors of metabolism and certain autoimmune diseases. It may also prove beneficial in solid organ transplantation.
It has been suggested that intravenously infused hematopoietic stem and progenitor cells return to the BM through a specific 'homing' process. 17 However, a study in the syngeneic murine model indicated that only 10% of infused stem cells migrated directly to the BM compartment after i.v. injection. 5, 18 The migration of donor stromal and hematopoietic stem cells into BM may be minimal after i.v. BMT because some hematopoietic stem cells lack homing receptors. 9, 19 The cells which do not reach the BM are probably trapped by other organs such as the liver and lungs, which have large capillary beds. 20 In our previous studies, we induced chimerism and tolerance in a rat hind limb composite tissue allotransplant 6 BMCs transplantation delivered intraosseously under 7 days of ab-TCR/CsA protocol. Significances of differences between means were calculated using the Mann-Whitney U-test. Differences among groups were considered significant at Po0.05. model across an MHC barrier. 21, 22 The limb allograft contains bone, which is a vascularized source of donorspecific hematopoietic cells and stromal cells, which facilitate donor-cell engraftment. We have also found that intraosseous BMT is more effective in inducing chimerism than is i.v. BMT. 14 The present study extends our observations on donor-cell engraftment into the BM and lymphoid tissues of recipients. We have established that not only the type of BMT (intraosseous or i.v.) but also the number of transplanted cells affects donor-cell engraftment. In our rat model, 70 Â 10 6 BMC transplanted directly into the bone under a 7-day ab-TCR/CsA protocol proved to be 40% more efficient for donor-cell engraftment compared with transplantation of 35 Â 10 6 cells (engraftment rates of 7.9 vs 4.8%, respectively). Moreover, intraosseous BMT of 70 Â 10 6 cells followed by 7 days of CsA monotherapy resulted in improved engraftment of donor cells compared with transplanting 35 Â 10 6 cells (3.8 vs 2.2%, respectively). The significantly higher chimerism level in the peripheral blood of long-term survival recipients also demonstrates improved engraftment of donor hematopoietic cells into the BM compartment of recipients after intraosseous BMC transplantation. Among animals that survived long-term (250 days), those that underwent the ab-TCR/CsA protocol and intraosseous BMC delivery exhibited higher chimerism than those that received standard i.v. BMC transplantation. Among untreated animals that survived long-term, chimerism was almost equal after i.v. and intraosseous BMC transplantation but was significantly lower compared with that of animals which had received ab-TCR/CsA treatment. These results also establish the superior effect of ab-TCR/CsA therapy for donor-cell engraftment. Moreover, they are consistent with the study by Huang et al. In the current study we did not observe GVHD independent of the treatment protocol. However, our immunosuppressive protocols significantly differ from the protocols used in the clinic. Our protocol of ab-TCR/CsA or CsA therapy was administered for only 7 days, and animals survived without long-term immunosuppression up to 250 days post transplant. However, this result arose not only from the adopted immunosuppressive protocol but also from the dosage of transplanted BMC. In experimental studies where GVHD developed in the comparable rat model, the number of transplanted allogenic BMC was higher than that in our study: GVHD was induced after transplantation of 100 Â 10 6 T-cell depleted BMC into total-body irradiated rats, 23 whereas in our model the highest dosage of BMC was 70 Â 10 6 and animals did not undergo myeloablative therapy. Moreover, in experimental studies in which the effect of different doses of tacrolimus was used to prevent GVHD after whole-organ or cell suspension transplantation, the dosage of BMC was significantly higher than in our study, specifically 2.5 Â 10 8 cells. 25 Moreover, in these studies, neither the untreated nor treated groups showed signs of GVHD after BMT. These results too are consistent with our observations. However, cell suspensions of splenocytes and lymph node leukocytes transplanted with the same dosage of BMC have invariably resulted in fatal GVHD under tacrolimus immunosuppression. 25 The absence of GVHD in our model probably resulted from the temporary selective depletion of mature ab-TCR cells, which control immunologic response and thus can cause GVHD when they are present. However, increase in the intensity of conditioning regimens and aggressive T-cell depletion also promotes the occurrence of GVHD. 7, 23 Conversely, in the rat model persistence of a CD8 þ / CD3 þ /TCR-population of T cells, characterized as facilitating cells, increases the engraftment of donor cells and minimizes GVHD. 23 The facilitating role of CD8 þ cells has also been demonstrated in a murine model. Irradiated mice which received CD8 þ T cells showed improved engraftment of donor cells, complete donor-cell chimerism and no evidence of GVHD. 7, 26 In our study, the facilitating effect of engraftment was accomplished under ab-TCR/ CsA protocol, which temporarily eliminated ab-TCR positive cells, which are predominantly CD4 T cells. However, gd positive cells (that also belong to the CD8 þ subpopulation of T cells) were not eliminated under our protocol.
We recently observed that 'crude' BM allotransplantation, which preserves the natural microenvironment of the graft and does not require marrow processing, significantly extended skin allograft survival. 27 It is well documented that donor stromal cells are essential for successful allogenic BMT. 28 In our model, we transplanted whole BM rather than a selected population of BMC, and we delivered BM directly into the natural BM microenvironment. The advantage of this approach lies in the fact that unselected BMC contain stem cells, progenitor cells, stromal cells and their precursors, all of which facilitate donor-cell engraftment.
Our data indicate that the seeding efficacy of donor cells into lymphoid tissues was greater after intraosseous BMT under ab-TCR/CsA protocol compared with standard i.v. BMT. The higher number of donor cells in the thymus of recipients after intraosseous BMT and the lower number of donor cells after i.v. BMT may be explained by the fact that although thymic dendritic cells can be replaced by donor marrow progenitors, this replacement requires irradiation. 29 In contrast, the lymph nodes and spleen are more easily reached by donor-derived cells because they are colonized soon after BMT through mature donor cells.
Intraosseous transplantation of BMC was shown to be a more effective strategy for hematopoietic cell engraftment in rodents. In a preclinical study, the effect of the route of mesenchymal stem cell (MSC) administration was tested in primates. 13 The investigators did not find intrabone MSC administration to be more effective than i.v. MSC delivery. These results differ from our observations. It should be pointed out, however, that in this primate model, MSC were genetically modified before transplantation and that different treatment protocols (for example, total-body or hemibody irradiation) were adopted. 13 Direct intraosseous BMT could be employed as a supportive therapy in solid organ transplantation and as an innovative approach for BMT in treating hematologic malignancies. In clinical practice, direct intraosseous transplantation has in fact been used to treat the latter. 30 However, the investigators did not observe faster hematopoietic recovery after intraosseous transplantation compared with standard i.v. BMT. Nevertheless, this method of BMT did fully protect against the development of bacteriemia. 30 Long hematopoietic recovery and graft failure arise as frequent complications when the number of available stem cells is limited. Intraosseous BMT may therefore provide an acceptable alternative in restrictive circumstances, as when the number of cells to be transplanted is limited; for example, in the transplantation of cord blood cells. 6 There are additional circumstances in which this innovative method of direct intraosseous BMT could be applied: (1) when transplanting a highly selected cell population; 9,10 (2) when transplanting a selected cell population modified by gene transfer; (3) in organ transplants as supportive therapy for inducing donor-specific immune unresponsiveness; 8, 11 and (4) as a more effective method of co-transplanting hematopoietic and MSCs 12 or in conjunction with donor lymphocyte infusion. 7 In summary, our study supports the view that short-term selective T-cell depletion under ab-TCR/CsA protocol combined with intraosseous BMT (70 Â 10 6 ) is more efficient method for donor-cell engraftment when compared to i.v. BMC delivery. This was confirmed by induction and maintenance of donor-specific chimerism in the peripheral blood and BM compartment of recipients.
